JPND launches €23 million call for neurodegenerative disease research
Posted: 16 January 2017 | Niamh Marriott (Drug Target Review) | No comments yet
Neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease are a global health, economic and social emergency.
The EU Joint Programme – Neurodegenerative Disease Research (JPND) has announced a joint trans-national call for research projects for pathway analysis across neurodegenerative diseases.
The unmet need
More than 40 million people worldwide are estimated to be living with Alzheimer’s disease and related disorders – the most common class of neurodegenerative disease – and this figure is expected to significantly increase in the coming decades.
Yet, with the exception of a few cases, no curative treatment exists, and the basic underlying mechanisms of many neurodegenerative diseases remain poorly understood.
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
With this in mind, JPND has identified an urgent need for targeted investment to better understand the fundamental links between different diseases. There is already clinical, genetic and biochemical evidence that similar molecular pathways are relevant in different neurodegenerative and other chronic diseases.
Trans-national research effort
This call will see €23 million made available to applicants from 20 countries. It invites proposals for ambitious, innovative, multinational and multidisciplinary collaborative research projects to perform network analyses across diseases in order to further elucidate the common underlying mechanisms involved.
This combined analysis could lead to a re-definition of clinical phenotypes and new approaches in the treatment of neurodegenerative diseases.
According to Professor Philippe Amouyel, Chair of JPND:
“JPND recognises that a critical step in the path to effective treatments or preventive strategies for neurodegenerative diseases is a deeper understanding of the underlying mechanisms of these diseases. What recent research has made clear is that these conceptual advancements will require greater thinking across traditional clinical boundaries. With this call, some €23 million will be made available to applicants to develop highly specialised cross-border projects that could lead to a better understanding of the biological underpinnings of neurodegenerative disease. Our hope is that these developments will in turn lead to new, outside-the-box diagnostic and therapeutic approaches.”
Neurodegenerative diseases
The neurodegenerative diseases included in the call are Alzheimer’s disease and other dementias, Parkinson’s disease (PD) and PD‐related disorders, prion diseases, motor neuron diseases (such as ALS), Huntington’s disease, spinocerebellar ataxia (SCA) and spinal muscular atrophy (SMA).
More information about the call is available here
Related topics
Analysis, Drug Leads, Drug Targets, Funding
Related conditions
Alzheimer’s disease, Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Parkinson's disease, spinal muscular atrophy (SMA), spinocerebellar ataxia (SCA)
Related organisations
Joint Programme – Neurodegenerative Disease Research (JPND)
Related people
Professor Philippe Amouyel
